{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:26:18Z","timestamp":1766157978520},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T00:00:00Z","timestamp":1469491200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2523-7","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T15:37:27Z","timestamp":1469547447000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study"],"prefix":"10.1186","volume":"16","author":[{"given":"Jianqiu","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingchao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuoxing","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiewen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuenong","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingmin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhi","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zimin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongjian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jifeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,26]]},"reference":[{"key":"2523_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"2523_CR2","doi-asserted-by":"publisher","first-page":"iv141","DOI":"10.1093\/annonc\/mdq692","volume":"22","author":"X Li","year":"2011","unstructured":"Li X, Li G, Gao Z, Zhou X, Zhu X. The relative frequencies of lymphoma subtypes in China: A nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol. 2011;22:iv141.","journal-title":"Ann Oncol"},{"issue":"Suppl 7","key":"2523_CR3","doi-asserted-by":"publisher","first-page":"vii78","DOI":"10.1093\/annonc\/mds273","volume":"23","author":"H Tilly","year":"2012","unstructured":"Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O, Andre M, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii78\u201382.","journal-title":"Ann Oncol"},{"key":"2523_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.6004\/jnccn.2013.0037","volume":"11","author":"AD Zelenetz","year":"2013","unstructured":"Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, et al. Non-Hodgkin\u2019s lymphomas, version 1.2013. J Natl Compr Canc Netw. 2013;11:257\u201372.","journal-title":"J Natl Compr Canc Netw"},{"key":"2523_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den NE, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116:2040\u20135.","journal-title":"Blood"},{"key":"2523_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"2523_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379\u201391.","journal-title":"Lancet Oncol"},{"key":"2523_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105\u201316.","journal-title":"Lancet Oncol"},{"key":"2523_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00277-011-1375-0","volume":"91","author":"X Li","year":"2012","unstructured":"Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B-cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Ann Hematol. 2012;91:837\u201345.","journal-title":"Ann Hematol"},{"key":"2523_CR10","first-page":"257","volume":"33","author":"ZX Cheng","year":"2012","unstructured":"Cheng ZX, Zou SH, Li F, Li JM, Wang JM, Chen FY, et al. Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up. Zhonghua Xue Ye Xue Za Zhi. 2012;33:257\u201360.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2523_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/annonc\/mdg070","volume":"14","author":"S Limat","year":"2003","unstructured":"Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol. 2003;14:277\u201381.","journal-title":"Ann Oncol"},{"key":"2523_CR12","doi-asserted-by":"publisher","first-page":"5212","DOI":"10.1016\/j.ijcard.2013.08.033","volume":"168","author":"W Jurczak","year":"2013","unstructured":"Jurczak W, Szmit S, Sobocinski M, Machaczka M, Drozd-Sokolowska J, Joks M, et al. Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study. Int J Cardiol. 2013;168:5212\u20137.","journal-title":"Int J Cardiol"},{"key":"2523_CR13","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1001\/jama.2013.281115","volume":"310","author":"M Mitka","year":"2013","unstructured":"Mitka M. FDA: Increased HBV reactivation risk with ofatumumab or rituximab. JAMA. 2013;310:1664.","journal-title":"JAMA"},{"key":"2523_CR14","first-page":"521","volume":"32","author":"WP Liu","year":"2011","unstructured":"Liu WP, Zheng W, Wang XP, Song YQ, Xie Y, Tu MF, et al. An analysis of hepatitis B virus infection rate in 405 cases of non-Hodgkin lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2011;32:521\u20134.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2523_CR15","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/cncr.22549","volume":"109","author":"F Wang","year":"2007","unstructured":"Wang F, Xu RH, Han B, Shi YX, Luo HY, Jiang WQ, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer. 2007;109:1360\u20134.","journal-title":"Cancer"},{"key":"2523_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00277-008-0469-9","volume":"87","author":"MH Chen","year":"2008","unstructured":"Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW, et al. High prevalence of occult hepatitis B virus infection in patients with B-cell non-Hodgkin\u2019s lymphoma. Ann Hematol. 2008;87:475\u201380.","journal-title":"Ann Hematol"},{"key":"2523_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","volume":"89","author":"SN Pei","year":"2010","unstructured":"Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89:255\u201362.","journal-title":"Ann Hematol"},{"key":"2523_CR18","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1016\/j.ejim.2013.07.008","volume":"24","author":"K Turker","year":"2013","unstructured":"Turker K. Awareness of hepatitis B virus reactivation among physicians authorized to prescribe chemotherapy. Eur J Intern Med. 2013;24:e90\u20132.","journal-title":"Eur J Intern Med"},{"key":"2523_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1200\/JOP.2012.000597","volume":"8","author":"RS Lee","year":"2012","unstructured":"Lee RS, Bell CM, Singh JM, Hicks LK. Hepatitis B screening before chemotherapy: a survey of practitioners\u2019 knowledge, beliefs, and screening practices. J Oncol Pract. 2012;8:325\u20138.","journal-title":"J Oncol Pract"},{"key":"2523_CR20","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3109\/10428194.2014.947606","volume":"56","author":"S Lu","year":"2015","unstructured":"Lu S, Xu Y, Mu Q, Cao L, Chen J, Zhu Z, et al. The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative\/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy. Leuk Lymphoma. 2015;56:1027\u201332.","journal-title":"Leuk Lymphoma"},{"key":"2523_CR21","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol. 1999;17:1244\u201353.","journal-title":"J Clin Oncol"},{"key":"2523_CR22","unstructured":"Consensus on the management of lymphoma in patients with hepatitis B virus infection. Zhonghua Gan Zang Bing Za Zhi 2013;21:815-20."},{"key":"2523_CR23","unstructured":"Consensus on the management of lymphoma with HBV infection. Zhonghua Xue Ye Xue Za Zhi 2013;34:988-93."},{"key":"2523_CR24","first-page":"53","volume":"29","author":"Y Xie","year":"2009","unstructured":"Xie Y, Zhu J, Zheng W, Zhang YT, Wang XP, Song YQ, et al. Clinical observation on rituximab combined with chemotherapy in the treatment of diffused large B-cell lymphoma. Tumor. 2009;29:53\u20137.","journal-title":"Tumor"},{"key":"2523_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1471-2407-8-115","volume":"8","author":"F Wang","year":"2008","unstructured":"Wang F, Xu RH, Luo HY, Zhang DS, Jiang WQ, Huang HQ, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008;8:115.","journal-title":"BMC Cancer"},{"key":"2523_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s12032-014-0845-3","volume":"31","author":"Z Wei","year":"2014","unstructured":"Wei Z, Zou S, Li F, Cheng Z, Li J, Wang J, et al. HBsAg is an independent prognostic factor in diffuse large B-cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China. Med Oncol. 2014;31:845.","journal-title":"Med Oncol"},{"key":"2523_CR27","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJM200006223422506","volume":"342","author":"K Benson","year":"2000","unstructured":"Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878\u201386.","journal-title":"N Engl J Med"},{"key":"2523_CR28","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","volume":"342","author":"J Concato","year":"2000","unstructured":"Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887\u201392.","journal-title":"N Engl J Med"},{"key":"2523_CR29","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJM200006223422511","volume":"342","author":"SJ Pocock","year":"2000","unstructured":"Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med. 2000;342:1907\u20139.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2523-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2523-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2523-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2523-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T03:41:28Z","timestamp":1506138088000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2523-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,26]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2523"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2523-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,26]]},"article-number":"537"}}